这项研究评估了双侧网状骶棘韧带悬吊术(MSSLS)与腹腔镜骶结肠切除术(LSC)在子宫脱垂患者中的疗效。从2021年1月至2023年1月在我院评估了98例子宫脱垂患者。采用随机数字表法将患者平均分为两组:研究组(接受MSSLS)和对照组(接受LSC)。各种参数,包括运行时间,出血量,留置导尿管时间,排气时间,住院,盆腔器官脱垂阶段,术后复发率,疼痛严重程度,生活质量,盆底功能,对性生活的影响,并发症,记录复发率。研究组显示手术时间显著缩短,出血量,留置导尿管时间,排气时间,住院时间与对照组比较(P<0.05)。Aa没有显著差异,Ba,Ap,Bp,术前两组比较(P>0.05),但是术后六个月,研究组患者的上述指标均显著降低(P<0.05)。两组患者术前疼痛程度差异无统计学意义(P>0.05)。但研究组术后6个月明显低于对照组(P<0.05)。生活质量,盆底功能,术前性生活质量无显著差异,6个月时,术后12个月(P>0.05)。所有患者随访12~14个月。平均随访时间(13.02±1.36)个月。研究组并发症发生率明显低于对照组(P<0.05)。但是两组都没有复发,差异无统计学意义(P>0.05)。MSSLS是一种安全有效的子宫脱垂治疗方法,显著降低并发症和复发率,使其适合广泛的临床应用。
This study assesses the efficacy of bilateral mesh sacrospinous ligament suspension (MSSLS) compared to laparoscopic sacrocolpopexy (LSC) in patients with uterine prolapse. Ninety-eight patients with uterine prolapse were evaluated at our hospital from January 2021 to January 2023. Patients were equally divided into two groups: the study group (undergoing MSSLS) and the control group (undergoing LSC) using a random number table. Various parameters including operation time, bleeding volume, indwelling catheter time, exhaust time, hospital stay, pelvic organ prolapse stage, postoperative recurrence rate, pain severity, quality of life, pelvic floor function, impact on sexual life, complications, and recurrence rate were recorded. The study group showed significant reductions in operation time, bleeding volume, indwelling catheter time, exhaust time, and hospital stay compared to the control group (P < 0.05). There were no significant differences in Aa, Ba, Ap, Bp, and C between the two groups before surgery (P > 0.05), but six months postoperatively, these indexes were significantly lower in the study group (P < 0.05). Pain severity did not differ significantly between the two groups before surgery (P > 0.05), but was significantly lower in the study group six months postoperatively (P < 0.05). Quality of life, pelvic floor function, and sexual life quality did not significantly differ before surgery, at 6 months, and at 12 months postoperatively (P > 0.05). All patients were followed up for 12-14 months, with an average follow-up time of (13.02 ± 1.36) months. The incidence of complications was significantly lower in the study group (P < 0.05), but there were no recurrences in either group, thus the difference was not statistically significant (P > 0.05). MSSLS emerges as a safe and efficacious treatment for uterine prolapse, notably reducing both complications and recurrence rates, rendering it suitable for broad clinical application.